Interpace Biosciences, Inc. IDXG

Company Overview

Interpace Biosciences, Inc. (NASDAQ: IDXG) is a molecular diagnostics and precision medicine company focused on developing and commercializing diagnostic tests for cancer risk assessment and disease stratification. The company primarily operates within the biotechnology and molecular diagnostics industries, with a concentration on gastrointestinal and endocrine cancers. Its core revenue drivers have historically included proprietary molecular diagnostic assays used by physicians to evaluate indeterminate thyroid nodules and pancreatic cysts.

The company’s principal products have included PancraGEN, ThyGeNEXT, and ThyraMIR, which are designed to assist clinicians in making treatment and surgical decisions through genomic and molecular analysis. Interpace Biosciences has positioned itself within the specialized oncology diagnostics market by combining molecular testing with pathology support services aimed at reducing unnecessary surgeries and improving diagnostic accuracy. The company evolved from earlier healthcare and diagnostic operations through restructurings and strategic shifts toward precision oncology and molecular testing services. Public filings and historical investor materials indicate the company transitioned over time from broader healthcare service operations into a focused diagnostics platform.